BioCentury
ARTICLE | Clinical News

Specifid mitumprotimut-T: Phase III data

June 2, 2008 7:00 AM UTC

Favrille discontinued development of Specifid after the compound missed the primary endpoint of a significant improvement in median TTP compared with placebo in a U.S. Phase III trial in 349 patients....